ARCA biopharma, Inc. (ABIO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABIO Stock Price Chart Interactive Chart >
ABIO Price/Volume Stats
| Current price | $2.42 | 52-week high | $3.90 |
| Prev. close | $2.41 | 52-week low | $1.71 |
| Day low | $2.40 | Volume | 35,000 |
| Day high | $2.44 | Avg. volume | 143,555 |
| 50-day MA | $2.35 | Dividend yield | N/A |
| 200-day MA | $2.42 | Market Cap | 34.87M |
ARCA biopharma, Inc. (ABIO) Company Bio
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Latest ABIO News From Around the Web
Below are the latest news stories about ARCA biopharma Inc that investors may wish to consider to help them evaluate ABIO as an investment opportunity.
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for GencaroTM compared to metoprolol WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision med |
Financial Survey: ARCA biopharma (ABIO) & Its PeersARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations. Risk & Volatility ARCA biopharma has [] |
Head-To-Head Contrast: ARCA biopharma (ABIO) and Its PeersARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Risk and Volatility ARCA biopharma has [] |
Contrasting ARCA biopharma (ABIO) & Its PeersARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its peers? We will compare ARCA biopharma to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current [] |
Indices - Reviewing ARCA biopharma & Its PeersARCA biopharma is one of 38 public companies in the Diagnostic substances industry, but how does it contrast to its peers? We will compare ARCA biopharma to related |
ABIO Price Returns
| 1-mo | 2.11% |
| 3-mo | 19.21% |
| 6-mo | 2.33% |
| 1-year | -30.66% |
| 3-year | -60.65% |
| 5-year | -94.51% |
| YTD | 12.56% |
| 2021 | -46.38% |
| 2020 | -29.78% |
| 2019 | -3.86% |
| 2018 | -75.56% |
| 2017 | -52.63% |
Loading social stream, please wait...